Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Bicycle Therapeutics plc BCYC

Healthcare Biotechnology
Bicycle Therapeutics plc is a United Kingdom-based clinical-stage biopharmaceutical company developing a novel class of medicines, referred to as Bicycle molecules, for diseases that are underserved by existing therapeutics. Bicycle molecules are fully synthetic short peptides constrained with small molecule scaffolds to form two loops that stabilize their structural geometry. The Company is... see more

Recent & Breaking News (NDAQ:BCYC)

Bicycle Therapeutics Announces Settlement of Patent Dispute with Pepscan Systems B.V.

Business Wire November 20, 2020

Bicycle Therapeutics to Present at the Jefferies Virtual London Healthcare Conference

Business Wire November 12, 2020

Bicycle Therapeutics Presents Posters at the SITC 35th Anniversary Annual Meeting

Business Wire November 9, 2020

Bicycle Therapeutics Reports Third Quarter 2020 Financial Results and Provides Corporate Update

Business Wire November 5, 2020

Bicycle Therapeutics Announces Expansion of Scientific Advisory Board

Business Wire October 21, 2020

Bicycle Therapeutics to Present Posters at the SITC 35th Anniversary Annual Meeting

Business Wire October 14, 2020

Bicycle Therapeutics Announces Gross Proceeds of $50.0 Million from its At-the-Market Offering Program and Enters into Debt Financing from Hercules Capital

Business Wire October 1, 2020

Bicycle Therapeutics to Present Trials in Progress Poster for BT8009 at the ESMO Virtual Congress 2020

Business Wire September 14, 2020

Bicycle Therapeutics Announces First Patient Dosed in Phase I/II Trial of Bicycle® Toxin Conjugate BT8009 in Patients with Advanced Solid Tumors

Business Wire September 10, 2020

Bicycle Therapeutics to Participate in Upcoming Virtual Investor Conferences

Business Wire September 3, 2020

Bicycle Therapeutics Announces First Patient Dosed in Phase IIa Trial of Bicycle® Toxin Conjugate BT1718

Business Wire September 2, 2020

Bicycle Therapeutics Announces First Patient Dosed in Oxurion's Phase II Trial Using a Novel Bicycle®-based Plasma Kallikrein Inhibitor for the Treatment of Diabetic Macular Edema

Business Wire September 1, 2020

Bicycle Therapeutics Appoints Dr. Dominic Smethurst as Chief Medical Officer

Business Wire August 11, 2020

Bicycle Therapeutics to Present at the Canaccord Genuity 40th Annual Growth Conference

Business Wire August 5, 2020

Bicycle Therapeutics Reports Second Quarter 2020 Financial Results and Provides Corporate Update

Business Wire August 5, 2020

Bicycle Therapeutics Appoints Sir Keith Peters as Chairman of Its Scientific Advisory Board

Business Wire June 23, 2020

Bicycle Therapeutics Presents New Translational Data for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at AACR Virtual Annual Meeting II

Business Wire June 22, 2020

Bicycle Therapeutics to Present at Upcoming Investor Conferences

Business Wire May 27, 2020

Bicycle Therapeutics to Present New Translational Research for BT5528 and Preclinical Data for Tumor-targeted Immune Cell Agonists at the AACR Virtual Annual Meeting II

Business Wire May 15, 2020

Bicycle Therapeutics to Present Trials in Progress Poster for BT5528 at the 2020 American Society of Clinical Oncology Virtual Meeting

Business Wire May 13, 2020